Scholarlink

<p>This matters arising addresses the recently published article in <i>BMC Medicine</i> by Tao Y et al., entitled “Effect of intravenous urokinase vs best medicine treatment on functional outcome for patients with acute minor stroke (TRUST): a randomized controlled trial.” While appreciating the rigorous methodology and important findings of the TRUST trial, we raise several points regarding optimizing urokinase dosing and treatment strategies. Specifically, we discuss the potential for optimizing urokinase dosing based on emerging evidence. Given China’s extensive clinical experience with urokinase and associated cost considerations, we advocate for further research, including trials evaluating weight-based dosing strategies, to optimize urokinase thrombolytic therapy for patients with acute ischemic stroke. Such research is crucial for optimizing urokinase thrombolysis and establishing its role as a cost-effective treatment option, especially in resource-limited settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A matters arising: discussion on urokinase dosing and individualized treatment strategies in the TRUST trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月28日

查看全文
  • Yue Qiao,
  • Xunming Ji,
  • Wenbo Zhao

摘要

This matters arising addresses the recently published article in BMC Medicine by Tao Y et al., entitled “Effect of intravenous urokinase vs best medicine treatment on functional outcome for patients with acute minor stroke (TRUST): a randomized controlled trial.” While appreciating the rigorous methodology and important findings of the TRUST trial, we raise several points regarding optimizing urokinase dosing and treatment strategies. Specifically, we discuss the potential for optimizing urokinase dosing based on emerging evidence. Given China’s extensive clinical experience with urokinase and associated cost considerations, we advocate for further research, including trials evaluating weight-based dosing strategies, to optimize urokinase thrombolytic therapy for patients with acute ischemic stroke. Such research is crucial for optimizing urokinase thrombolysis and establishing its role as a cost-effective treatment option, especially in resource-limited settings.